John Paul Leonard

John Paul Leonard's AcademicInfluence.com Rankings

John Paul Leonard

Philosophy

#7281

World Rank

#10473

Historical Rank

Logic

#4336

World Rank

#5615

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John Paul Leonard's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is John Paul Leonard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John Paul Leonard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. (2010) (1243)
Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma (2018) (1081)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. (2010) (778)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006) (706)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. (2010) (679)
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. (2009) (668)
Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production (1997) (648)
Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 (1995) (610)
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. (2001) (576)
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. (1997) (424)
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. (2002) (371)
The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura (2004) (324)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. (2009) (322)
Outcome of deferred initial therapy in mantle-cell lymphoma. (2009) (318)
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. (2011) (304)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. (2012) (290)
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. (2008) (266)
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma (2009) (252)
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. (2014) (249)
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. (2003) (246)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. (2005) (246)
A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma (2009) (235)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. (2016) (224)
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma (2004) (219)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma (2019) (208)
Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma (2002) (208)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
Postibrutinib outcomes in patients with mantle cell lymphoma. (2016) (204)
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. (2014) (202)
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. (2015) (198)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. (2019) (198)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. (2008) (191)
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. (2003) (191)
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. (2008) (189)
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. (2011) (180)
IL-23 Is Critical in the Induction but Not in the Effector Phase of Experimental Autoimmune Encephalomyelitis (2007) (180)
FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease (2006) (169)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. (2005) (168)
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. (2005) (162)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity (2014) (159)
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). (2015) (157)
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. (2005) (156)
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. (2013) (154)
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. (2009) (153)
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. (2005) (153)
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. (2010) (153)
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy (2004) (140)
Idelalisib-associated Colitis: Histologic Findings in 14 Patients (2015) (129)
Cytosolic phospholipase A2α–deficient mice are resistant to experimental autoimmune encephalomyelitis (2005) (127)
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. (2015) (125)
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. (2007) (120)
Immunotherapy of Non-Hodgkin's lymphomas. (2001) (118)
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. (2017) (116)
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma (2007) (116)
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. (2008) (109)
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. (2016) (108)
Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. (1997) (102)
Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 (2016) (101)
Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. (1994) (101)
Durable complete responses from therapy with combined epratuzumab and rituximab (2008) (100)
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies (2007) (98)
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. (2009) (97)
A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma (2006) (96)
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. (2006) (92)
Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R (2017) (90)
Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy (2007) (88)
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. (2005) (87)
Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non–Hodgkin's Lymphoma (2006) (86)
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. (2013) (83)
Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. (1996) (83)
A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era (2014) (81)
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors (2019) (80)
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. (2013) (79)
Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. (2002) (78)
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. (2017) (78)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. (2008) (75)
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. (2018) (75)
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (2019) (74)
Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L (2012) (74)
Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790 (1995) (74)
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. (2018) (72)
Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL) (2008) (71)
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. (2014) (71)
Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. (2019) (71)
Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. (1999) (71)
TH1-mediated airway hyperresponsiveness independent of neutrophilic inflammation. (2005) (71)
BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia (2002) (70)
Motivation for Health Information Seeking and Processing About Clinical Trial Enrollment (2010) (69)
Changes in lymphocyte β-adrenergic receptor density and noradrenaline content of the spleen are early indicators of immune reactivity in acute experimental allergic encephalomyelitis in the Lewis rat (1989) (69)
Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. (2021) (68)
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. (2014) (66)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. (2010) (64)
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1 (2013) (63)
Repeated courses of rituximab in chronic ITP: Three different regimens (2009) (62)
Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib (2010) (62)
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma (2007) (61)
Regulation of the inflammatory response in animal models of multiple sclerosis by interleukin-12. (1997) (61)
Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. (1996) (60)
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP‐C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low‐dose metronomic, multidrug therapy (2008) (59)
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. (2015) (59)
A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degeneration. (2002) (58)
Proteasome inhibition with bortezomib: A new therapeutic strategy for non‐Hodgkin's lymphoma (2006) (58)
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib (2008) (57)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. (2016) (57)
Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12 – Associated Toxicity and Interferon-g Production (1997) (57)
Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas. (2008) (57)
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 (2013) (55)
Biology and management of mantle cell lymphoma (2001) (54)
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. (2012) (54)
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma (2010) (53)
Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma (2010) (53)
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. (2017) (52)
From information processing to behavioral intentions: exploring cancer patients' motivations for clinical trial enrollment. (2010) (52)
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. (2020) (52)
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. (2018) (50)
Epratuzumab: targeting B-cell malignancies through CD22. (2003) (50)
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. (2010) (50)
Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. (2010) (50)
Information Seeking Related to Clinical Trial Enrollment (2011) (49)
Phase 1 trial of bortezomib plus R‐CHOP in previously untreated patients with aggressive non‐Hodgkin lymphoma (2010) (49)
β‐Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: A regulatory role for cortisol and interleukin‐1 (1992) (49)
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). (2002) (47)
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. (2003) (47)
Changes in hypothalamic corticotrophin-releasing factor and anterior pituitary pro-opiomelanocortin mRNA during the course of experimental allergic encephalomyelitis (1993) (47)
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma (2008) (46)
CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. (2014) (46)
A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. (2001) (46)
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. (2019) (46)
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) (2017) (45)
Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202 (2014) (45)
Retroviral Vectors for Production of Interleukin‐12 in the Bone Marrow to Induce a Graft‐Versus‐Leukemia Effect a (1996) (45)
Secondary Use of Patients' Electronic Records (SUPER): An Approach for Meeting Specific Data Needs of Clinical and Translational Researchers (2017) (44)
Toxicity burden score: a novel approach to summarize multiple toxic effects. (2012) (43)
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study (2012) (43)
Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis (1991) (43)
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. (2015) (42)
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma (2008) (42)
Regulation of Experimental Autoimmune Encephalomyelitis by Interleukin‐12 (1996) (41)
Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma (2008) (41)
Pilot Study of Aurora, a Social, Mobile-Phone-Based Emotion Sharing and Recording System (2011) (41)
A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. (1997) (40)
Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results. (2005) (39)
CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. (2012) (38)
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. (2013) (38)
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 (2021) (37)
Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 (2016) (37)
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. (2020) (37)
RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106 (2017) (36)
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies (2008) (36)
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients (2016) (36)
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. (2017) (35)
Improving outcomes for patients with Burkitt lymphoma and HIV. (2008) (35)
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. (2007) (35)
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity (2012) (34)
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918). (2015) (34)
The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. (2001) (34)
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. (2015) (34)
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2011) (34)
Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. (1997) (33)
Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy (2015) (32)
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. (2017) (32)
A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia, (2010) (32)
Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403 (2015) (31)
Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL) (2008) (31)
Individuals' Willingness to Talk to Their Doctors About Clinical Trial Enrollment (2010) (31)
Subsequent therapy can be administered after tositumomab and iodine I‐131 tositumomab for non‐Hodgkin lymphoma (2006) (31)
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. (2019) (31)
Mantle cell lymphoma: biological insights and treatment advances. (2009) (31)
Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. (2001) (31)
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). (2002) (30)
CD22-directed monoclonal antibody therapy for lymphoma. (2003) (30)
Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma. (2005) (29)
Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma (2017) (29)
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). (2017) (29)
Immunoregulation by interleukin‐12 in MB49.1 tumor‐bearing mice: Cellular and cytokine‐mediated effector mechanisms (1997) (29)
Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells. (1999) (29)
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma. (2015) (28)
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations (2017) (28)
Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. (1995) (27)
First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962). (2015) (27)
The role of FDG-PET imaging in the management of lymphoma. (2004) (27)
Hypothalamic PGE2 and cAMP production and adrenocortical activation following intraperitoneal endotoxin injection: in vivo microdialysis studies in Lewis and Fischer rats. (1994) (27)
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials (2018) (27)
Is there a role for "watch and wait" in patients with mantle cell lymphoma? (2011) (26)
BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity. (2012) (26)
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop (2011) (26)
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma (2015) (26)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study (2005) (25)
Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. (2003) (25)
Progress in mantle-cell lymphoma. (2009) (24)
Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. (1998) (24)
Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) (2013) (24)
Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604) (2015) (24)
Diabetes care management patterns before and after a cancer diagnosis: A SEER‐Medicare matched cohort study (2020) (24)
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma (2012) (24)
Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial. (2009) (23)
Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease. (2004) (23)
Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. (2005) (23)
Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL (2005) (23)
Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL. (2005) (23)
Cytosolic phospholipase A 2 – deficient mice are resistant to experimental autoimmune encephalomyelitis (2005) (22)
CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL) (2007) (22)
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. (2013) (22)
T‐Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment (2017) (22)
A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). (2012) (22)
beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. (1992) (22)
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients (2021) (21)
Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study (2020) (21)
Selective CDK 4 / 6 inhibition with tumor responses by PD 0332991 in patients with mantle cell lymphoma * (2012) (21)
Applying the theory of planned behavior to study health decisions related to potential risks (2010) (21)
Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT (2014) (21)
Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. (2006) (21)
Splenic noradrenergic and adrenocortical responses during the preclinical and clinical stages of adoptively transfered experimental autoimmune encephalomyelitis (EAE) (1990) (21)
Targeted treatment and new agents in diffuse large B-cell lymphoma. (2008) (20)
Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) (2005) (20)
Recommendations for Clinical Trial Development in Follicular Lymphoma (2017) (20)
Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma. (2007) (20)
Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma (2008) (20)
Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. (1998) (20)
A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (2013) (19)
Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma (2003) (19)
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma (2019) (19)
Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included). (2008) (19)
Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). (2013) (18)
Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228 (2005) (18)
A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM) (2016) (18)
Phase 2 Multicenter Trial of Gallium Nitrate in Patients with Advanced Non-Hodgkin’s Lymphoma (NHL). (2004) (18)
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort (2018) (18)
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas (2015) (18)
Epratuzumab in non-hodgkin’ lymphomas (2004) (17)
Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report (2014) (17)
A roadmap for discovery and translation in lymphoma. (2015) (17)
Phase I to III Trials of Anti–B Cell Therapy in Non–Hodgkin's Lymphoma (2007) (17)
Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation (2013) (17)
Superior outcomes associated with earlier use: Experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin’s lymphoma (NHL) (2005) (17)
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies. (2010) (17)
Exploiting genotypic differences to identify genes important for EAE development (2005) (16)
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study (2012) (16)
Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20) (2010) (16)
Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. (2006) (16)
Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) (2020) (16)
Up-regulation ofβ-adrenoceptors on circulating mononuclear cells after reduction of central sympathetic outflow by clonidine in normal subjects (1992) (16)
Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL). (2013) (16)
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma (2008) (16)
Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies. (2009) (16)
Monoclonal anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen: generation and characterization of anti-idiotype antibodies. (1991) (16)
DLBCL Cell of Origin: What Role Should It Play in Care Today? (2018) (16)
Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). (2013) (16)
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 (2020) (15)
SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL). (2006) (15)
Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity. (1996) (15)
A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results. (2014) (14)
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. (2008) (14)
Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results (2014) (14)
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent. (2019) (14)
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. (2016) (14)
A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor. (2016) (14)
Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM). (2005) (14)
Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability (2013) (14)
Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2014) (14)
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. (2019) (14)
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies (2019) (14)
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. (2014) (13)
Establishing the Feasibility of a Tablet-Based Consent Process with Older Adults: A Mixed-Methods Study (2019) (13)
Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. (2008) (13)
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic (2020) (13)
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001 (2019) (13)
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma (2015) (13)
Lenalidomide in follicular lymphoma. (2020) (13)
Comparing Decision Making Between Cancer Patients and the General Population: Thoughts, Emotions, or Social Influence? (2012) (13)
Management of relapsed mantle cell lymphoma: still a treatment challenge. (2009) (13)
SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) (2004) (13)
Concomitant diffuse large B‐cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: A study of two cases (2008) (13)
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. (2006) (12)
Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22 (2003) (12)
A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma (2016) (12)
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL) (2019) (12)
Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma (2014) (12)
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. (2018) (12)
The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL) (2004) (12)
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. (2009) (12)
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma (2017) (12)
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]. (2008) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. (2015) (11)
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement (2007) (11)
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies (2009) (11)
Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. (2013) (11)
ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma. (2021) (11)
Management of mantle cell lymphoma: key challenges and next steps. (2010) (11)
Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 ( hA 20): Phase I/II Results. (2006) (11)
New developments in immunotherapy for non-Hodgkin’s lymphoma (2005) (10)
Hodgkin's and Non-Hodgkin's Lymphoma (2006) (10)
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. (2020) (10)
Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results (2007) (10)
Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma (2009) (10)
Novel agents for follicular lymphoma. (2010) (10)
Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL). (2004) (10)
Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi- center phase II study of lenalidomide plus rituximab. (2013) (10)
Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies. (2008) (10)
Laboratory Workup of Lymphoma in Adults. (2020) (10)
AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (2018) (10)
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL) (2011) (10)
The potential for chemotherapy-free strategies in mantle cell lymphoma. (2017) (10)
Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance) (2016) (10)
Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) (2004) (10)
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation. (2015) (10)
A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (2017) (9)
SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (2020) (9)
A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement. (2004) (9)
Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30 (2005) (9)
Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas. (2020) (9)
Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. (2016) (9)
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). (2013) (9)
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance). (2021) (9)
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. (2008) (9)
Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701 (2021) (9)
Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study (2017) (9)
Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease. (2006) (9)
Prophylactic Low-Dose Aspirin Is Effective as Antithrombotic Therapy in Patients Receiving Combination Thalidomide or Lenalidomide. (2005) (9)
Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study (2020) (9)
Novel immunotherapy approaches to follicular lymphoma. (2018) (8)
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. (2012) (8)
Mantle cell lymphoma: current concept in biology and treatment. (2006) (8)
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (2018) (8)
Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity (2012) (8)
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab (2015) (8)
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas (2016) (8)
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts (2021) (8)
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL (2021) (8)
Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression. (2006) (8)
THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL (2017) (8)
Sequencing of therapies in relapsed follicular lymphoma. (2018) (8)
A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL). (2009) (8)
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance) (2019) (7)
Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. (2016) (7)
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL). (2021) (7)
Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis (2011) (7)
Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years in a Large Cohort of Patients Managed Primarily with Conservative Therapies. (2007) (7)
Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2014) (7)
Lymphoma "benchmark" or "bench-smudge"? (2017) (7)
Phase 2 multicentre study of single‐agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance) (2019) (7)
Lenalidomide Induced Myelosupression Is Potentially Associated with Renal Dysfunction in Treatment Naïve Myeloma (MM) Patients Receiving BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx). (2006) (7)
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials (2017) (7)
Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach (2018) (7)
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (2019) (7)
FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (2017) (7)
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma (2007) (7)
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. (2018) (7)
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma. (2014) (7)
Where to start? Upfront therapy for follicular lymphoma in 2018. (2018) (6)
Laboratory Workup of Lymphoma in Adults. (2020) (6)
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma (2021) (6)
Tositumomab and iodine I 131 tositumomab: Efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma (NHL) (2005) (6)
Gene therapy--the challenge for the future. (1996) (6)
Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (2021) (6)
New biologic agents and immunologic strategies. (2008) (6)
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance) (2018) (6)
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101. (2020) (6)
Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling (2019) (6)
A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma. (2009) (6)
New monoclonal antibodies for non-Hodgkin's lymphoma. (2008) (6)
The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial (2013) (6)
Interleukin-12 Gene Therapy Vaccines: Directing the Immune System against Minimal Residual Leukemia (2001) (6)
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. (2020) (6)
Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL. (2010) (6)
Impact of Course of Therapy on Response Rate and Duration with the Bexxar® Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab) and with Chemotherapy. (2004) (6)
The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). (2004) (6)
Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies (2011) (6)
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis. (2010) (6)
Combination treatment approaches and novel therapies for lymphoma. (2007) (6)
Oral combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide, procarbazine, cyclophosphamide): Low-dose continuous metronomic multidrug therapy (2007) (6)
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas (2021) (5)
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. (2010) (5)
Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016 (2018) (5)
CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL). (2009) (5)
Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas (2010) (5)
Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma (2020) (5)
Preliminary immune response (IR) results of a phase 2 study with idiotype (Id) immunotherapy after treatment with CVP and rituximab for follicular non-Hodgkin's lymphoma (FL). (2006) (5)
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). (2018) (5)
Mantle cell lymphoma: Report of the 2009 Mantle Cell Lymphoma Consortium Workshop (2010) (5)
Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance) (2015) (5)
Novel therapeutic targets in mantle cell lymphoma (2007) (5)
BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features. (2005) (5)
Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. (2020) (5)
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States (2018) (5)
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. (2021) (5)
The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). (2004) (5)
Lenalidomide plus Rituximab for Mantle-Cell Lymphoma. (2016) (5)
The THRIL (thalidomide [T], rituximab [R], and lenalidomide [L]) regimen for chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma: daily alternating IMiDs and rituximab maintenance (2008) (5)
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data* (2018) (5)
Targeting CD30 in hodgkin lymphoma: antibody-drug conjugates make a difference. (2012) (4)
B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder. (2006) (4)
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. (2016) (4)
Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016 (2016) (4)
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies (2019) (4)
Understanding the Differences between Clinical Trial Participants and Real-World Patients with Non-Hodgkin Lymphoma (2018) (4)
Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM). (2015) (4)
HDAC Profiling In Mantle Cell Lymphoma Unveils HDAC11 and HDAC10 as Potential Molecular Targets (2010) (4)
Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08) (2018) (4)
Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference (2012) (4)
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (4)
Racial disparities in diabetes care among incident breast, prostate, and colorectal cancer survivors: a SEER Medicare study (2021) (4)
Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL (2012) (4)
Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. (2009) (4)
Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma. (2007) (4)
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. (2021) (4)
Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma, (2011) (4)
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy. (2004) (4)
Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study. (2007) (3)
Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup. (2010) (3)
Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma. (2006) (3)
Tositumomab and Iodine I 131 Tositumomab (the BEXXAR® Therapeutic Regimen) Shows Efficacy in Elderly Patients (pts) with Relapsed/Refractory Low-Grade (LG), Follicular, and Transformed Non-Hodgkin’s Lymphoma (NHL). (2004) (3)
Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or Transformed Low Grade Non-Hodgkins Lymphoma (2002) (3)
Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia. (2004) (3)
Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study. (2021) (3)
Targeted therapies for non-Hodgkin lymphoma: rationally designed combinations. (2007) (3)
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma. (2019) (3)
Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas. (2006) (3)
Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy (2011) (3)
PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES (2019) (3)
A retrospective study of R‐DHAP/Ox for early progressing follicular lymphoma (2018) (3)
A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma (2008) (3)
The “FLIPI” is no “FLOPI” (2004) (3)
Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib. (2009) (3)
Periocular MALT Lymphomas (Conjunctival/Orbital): Complete Responses with Antibiotic Therapy. (2004) (3)
CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL) (2021) (3)
PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy (2016) (3)
Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) (2013) (2)
Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance) (2017) (2)
A worrisome interventricular septum: more than meets the eye. (2011) (2)
Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition (2012) (2)
Re-treatment with Tositumomab and Iodine I 131 Tositumomab in patients with non-Hodgkin lymphoma who had previously responded to Tositumomab and Iodine I 131 Tositumomab (2005) (2)
Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL). (2017) (2)
Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) (2019) (2)
General Biomarker Recommendations for Lymphoma. (2016) (2)
Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL). (2007) (2)
Reality of complementary and alternative medicine in lymphoma patients: Hope, hype, or help? (2009) (2)
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials (2022) (2)
Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401) (2015) (2)
IL-4 as therapy for non-Hodgkin's lymphoma: Possibilities but major challenges (2007) (2)
Abstract A11: Therapeutic targeting of GCB- and ABC-DLBCLS by rationally designed BCL6 inhibitors (2017) (2)
EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY: PF483 (2019) (2)
A phase 1 study evaluating the safety and tolerability of otlertuzumab , an anti-CD 37 mono-speci fi c ADAPTIR therapeutic protein in chronic lymphocytic leukemia (2014) (2)
Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (2022) (2)
Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1 (2022) (2)
Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis (2018) (2)
5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B) (2011) (2)
Abstract 10135: Cardiotoxicity and Mortality in Chimeric Antigen Receptor T Cell Therapy Recipients (2021) (2)
Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues (2011) (2)
Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens. (2006) (2)
Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. (2010) (2)
MULTI‐CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC‐486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T‐CELL LYMPHOMA (2019) (1)
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients. (2022) (1)
A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB- 743921 Administered on Days 1 and 15 Every 28 Days without and with Prophylactic G-CSF in Non-Hodgkin or Hodgkin Lymphoma. (2008) (1)
HSP90 facilitates oncogenic alterations of metabolism in B-cell lymphomas (2020) (1)
POD24 in follicular lymphoma: time to be "wise". (2022) (1)
Pediatric Hodgkin and Non-Hodgkin Lymphomas (2016) (1)
Daily Alternating of Immunomodulating Agents and Rituximab in Therapy for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma: The THRIL (Thalidomide [TH], Rituximab [RI], and Lenalidomide [L]) Regimen (2008) (1)
Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab (2008) (1)
A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas (2020) (1)
Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis (2015) (1)
An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission. (2010) (1)
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance) (2020) (1)
Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma (2022) (1)
HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL (2017) (1)
Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study (2017) (1)
ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy. (2018) (1)
A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non-Hodgkin’s or Hodgkin’s Lymphoma. (2007) (1)
IBCL-178: A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (2020) (1)
An architecture for research computing in health to support clinical and translational investigators with electronic patient data (2021) (1)
Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation (2011) (1)
Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities (2010) (1)
Unmet mental health needs in patients with advanced B-cell lymphomas (2021) (1)
TOP-M Chemotherapy (Thiotepa, Oncovin [Vincristine], Prednisone, Mitoxantrone) Plus Rituximab for Marginal Zone Lymphoma. (2004) (1)
Talking to Doctors About Clinical Trials (2008) (1)
Splenic lymphomas: is there still a role for splenectomy? (2012) (1)
Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data. (2006) (1)
Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission. (2007) (1)
Comparison of FDG- and FLT-PET/CT in a multi-center phase Ib trial of a novel anti-proliferative cyclin dependent kinase (cdk) inhibitor in treatment of recurrent mantle cell lymphoma (2008) (1)
Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611) (2016) (1)
XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells (2020) (1)
Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight) (2019) (1)
Phase I Trial ofToll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non^Hodgkin’s Lymphoma (2007) (1)
Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma (2010) (1)
New developments in the treatment of follicular lymphoma. (2019) (1)
Effects of Interleukin 12 on Hematopoietic Stem and Progenitor Cells (1996) (1)
A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) (2017) (1)
Multimodular Analysis of Angiogenic Biomarkers in the Primary Treatment of Multiple Myeloma: Correlative Studies of the BiRD Trial. (2005) (1)
A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) (2009) (1)
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816 (2020) (1)
Stromal Incorporation of VEGFR-1+, CD68+ and α-SMA+ Hemangiogenic Cells Correlates with Histologic Subtype in Non-Hodgkin’s Lymphoma. (2005) (1)
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma. (2023) (1)
A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies. (2018) (1)
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis (2021) (1)
Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study Identification. (2019) (1)
Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592) (2021) (1)
Management of Relapsed and Refractory Hodgkin Lymphoma in 2018. (2018) (1)
AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab. (2015) (1)
OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS (2017) (1)
FDG-PET scans in patients with lymphoma (2008) (1)
Highlights of the 45th Annual Meeting of the American Society of Hematology (2004) (1)
Ribavirin, an eIF4E Inhibitor, As a Potential Anti-Lymphoma Therapeutic - Preclinical and Early Clinical Data (2016) (1)
Abstract CT104: A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies (2019) (1)
Abstract 3095: Longitudinal integrative whole transcriptome and exome sequencing identifies genes that reprogram lymphoma cells for clinical response to CDK4/6 inhibition in combination therapy (2015) (0)
PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (2019) (0)
Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study (2022) (0)
Effect of the sphingolipid synthesis inhibitor, myriocin, in a murine pulmonary inflammation model (94.19) (2009) (0)
New agents in development for non-Hodgkin's lymphoma (2007) (0)
Continuing Medical Education and Patient Education on Follicular Lymphoma: Changes in Clinician Practice, Patient Behaviors, and Knowledge across Clinicians and Patients (2019) (0)
IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM) (2015) (0)
Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma (2018) (0)
AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). (2014) (0)
Splenic SUV on FDG-PET in NHL correlates with histopathology findings at splenectomy (2007) (0)
Higher Rates of Untreated Distress in Older Versus Younger Adults With Indolent Lymphoma (2020) (0)
Levels of Circulating Endothelial Cells and Endothelial Progenitors Correlate with Disease Status and Treatment Response in Human Lymphoma Subtypes of CLL and MCL. (2009) (0)
Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592) (2017) (0)
Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy (2013) (0)
Value of FDG-PET in Prediction of Splenectomy Findings in Patients with Suspected or Known Lymphoma. (2006) (0)
Hodgkin's lymphoma in HIV: unusual presentations and improving outcomes. (2003) (0)
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. (2006) (0)
Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis (2016) (0)
AUGMENT: phase III randomized study of lenalidomide+rituximab (R 2 ) vs rituximab in R/R iNHL patients (2019) (0)
ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia. (2009) (0)
Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma (2015) (0)
Oral Administration of the Opium Alkaloid Noscapine (NOS) Exhibits Potent Anti-Tumor Activity Against Non-Hodgkin’s Lymphomas and Myeloma Cell Lines In Vitro and In Vivo in SCID-beige Murine Xenograft Models. (2005) (0)
Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001 (2022) (0)
PTSD and lymphoma: Two very different psychological trajectories following a common diagnosis. (2017) (0)
PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT) (2019) (0)
CLINICAL TRIALS AND OBSERVATIONS Postibrutinib outcomes in patients with mantle cell lymphoma (2016) (0)
Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL) (2015) (0)
CD40LTNF-Related Factors BAFF, APRIL, and Lymphocytic Leukemia Cells through the Bidirectional Crosstalk with Chronic Stromal Endothelial Cells Establish a (2012) (0)
Doctor–Patient Interactions Regarding Clinical Trial Enrollment Questionnaire (2017) (0)
Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma (2019) (0)
Monoclonal Antibody Therapy of Lymphoma (2001) (0)
Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations (2020) (0)
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. (2023) (0)
Abstract 1523: Repression of IRF4 and CYTIP unleashes anti-tumor interferon response in CDK4 inhibitor therapy in mantle cell lymphoma (2018) (0)
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma. (2009) (0)
Randomised phase III study of alisertib or investigator's choice (selected singe agent) in patients with relapsed or refractory peripheral T-cell lymphoma (2017) (0)
Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data (2001) (0)
Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant MCL Cells for Killing by Proteasome Inhibitor Bortezomib by Activating Cell Cycle-Coupled Apoptosis (2008) (0)
Inhibitors of the Proteasome and mTOR (2010) (0)
Increased Resistance and Selection in Paclitaxel for Peripheral Blood Progenitor Cells Following Transduction with the MDR1 Gene (2000) (0)
Mantle Cell Lymphoma: Biologic Insights to Bedside Impact. (2020) (0)
Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance) (2022) (0)
Plasma Cell Myeloma and Plasma Cell Disorders (2017) (0)
Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy (2008) (0)
Comment on Crump et al , page 1800 Lymphoma “ benchmark ” or “ bench-smudge ” ? (2017) (0)
Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population (2012) (0)
T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma (2019) (0)
Lymphoma occurring during pregnancy (2013) (0)
Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas. (2022) (0)
Role of surveillance imaging in the management of peripheral T-cell lymphomas. (2014) (0)
Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6 (2011) (0)
Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study. (2013) (0)
Pivotal S tudy o f I odine I 1 31 T ositumomab f or Chemotherapy-Ref ractory L ow-Grade o r T ransformed Low-Grade B -Cell N on-Hodgkin's L ymphomas (2001) (0)
Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS) (2011) (0)
Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCγ2 Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib (2008) (0)
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma (2021) (0)
Racial Disparities in Diabetes-Related Emergency Department Visits and Hospitalizations Among Cancer Survivors (2022) (0)
Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411 (2022) (0)
Abstract 3424: Induction of prolonged early G1-arrest by CDK4/CDK6 inhibition reprograms cycling lymphoma cells for enhanced and sustained inhibition of PI3Kδ/AKT. (2013) (0)
A study of a non-myeloablative conditioning regimen followed by allogeneic stem cell transplant (NMT) for patients with hematological malignancies using campath as part of a graft versus host disease (GVHD) strategy. (2004) (0)
Variance in Practice between Experts and Oncology Healthcare Professionals for Follicular Lymphoma: Analysis of an Online Treatment Decision Tool (2021) (0)
ATTENUATION OF rmlL‐12 TOXICITY AND IFN‐y PRODUCTION BY PRETREATMENT WITH RMIL‐12: 332 (1997) (0)
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. (2022) (0)
APhase 2 Study of Rituximab in Combinationwith Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin ’ s Lymphoma (2006) (0)
Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis (2016) (0)
Introduction to Hematologic Malignancies (2017) (0)
Monoclonal Antibodies in Lymphomas (2007) (0)
Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma (2018) (0)
Rapid Response to COVID-19 by Mobilizing Numeric Data, Treatments such as HCQ+Zinc (2020) (0)
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study – Response to Adams and Kwee (2019) (0)
Immunotherapy of B-cell malignancies: first MABs, now SMIPs (2007) (0)
ICOS Receptor B 7-Like Protein That Functionally Binds to Cutting Edge : Identification of GL 50 , a Novel Miyashiro (2000) (0)
Antibodies in the treatment of lymphoma. (2004) (0)
Reply to H.E. Eve et al (2009) (0)
AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study (2019) (0)
A Pilot Study of a Sequential Regimen of Intensive Chemotherapy (Bendamustine-Bridge) Followed by Autologous or Allogeneic Transplantation for Refractory Lymphomas (2017) (0)
In vitro and in vivo expression regulation of PD-1 and PD-L1 in murine tumor models (2001) (0)
Abstract 3099: Longitudinal genomic and transcriptomic analysis of mantle cell lymphoma in a targeted combination trial of a selective CDK4/6 inhibitor (2015) (0)
Inadequate Illness Understanding and Suboptimal Levels of Advance Care Planning in Patients with Aggressive Lymphoma (2018) (0)
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients (2016) (0)
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey (2022) (0)
Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support. (2003) (0)
Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq (2019) (0)
Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset (2021) (0)
Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials. (2020) (0)
Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303) (2022) (0)
173: Stem-Cell Collection Prior to Autologous Stem Cell Transplantation is Improved by Cyclophosphamide in Lenalidomide-Treated Patients with Multiple Myeloma (2008) (0)
Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016 (2019) (0)
Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance] (2020) (0)
Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation (2014) (0)
The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval. (2017) (0)
Antibody treatment in lymphoma. (2009) (0)
Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab (2019) (0)
Abstract 3887: Reversible inhibition of CDK4/CDK6 sensitizes hematological tumor cells for cytotoxic killing by inducing sequential G1 arrest and synchronous S phase entry that enhances the intrinsic apoptosis pathway (2010) (0)
Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study. (2009) (0)
therapy for previously treated indolent non-Hodgkin lymphoma , as δ Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- (2014) (0)
Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration (2018) (0)
Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT). (2019) (0)
The role of in vivo PD-1/PD-L1 interactions in syngeneic and allogeneic antitumor responses in murine tumor models (2001) (0)
Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608 (2021) (0)
Diffuse variant of lymphocyte-predominant Hodgkin lymphoma: a diagnostic challenge (2013) (0)
Advancing through maintenance in mantle cell lymphoma (2011) (0)
review Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma (2009) (0)
Therapy for older patients with diffuse large cell lymphoma: Targeting the treatment to the patient (2007) (0)
Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance). (2020) (0)
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE. (2015) (0)
Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents. (2010) (0)
Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma (2019) (0)
Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions (2001) (0)
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis (2023) (0)
Evaluation of the Prognostic Utility of Bone Marrow Biopsy in Diffuse Large B-Cell Lymphoma: A SEER-Medicare Linked Database Analysis (2020) (0)
A study of a non-myeloablative conditioning regimen followed by allogeneic stem cell transplant (NMT) for patients with hematological malignancies using campath as part of a graft versus host disease (GVHD) strategy (2004) (0)
Reply to T.M. Weis et al. (2019) (0)
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with low-grade non-Hodgkins lymphoma treated with tositumomab and iodine-131 tositumomab therapeutic regimen (2003) (0)
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma? (2012) (0)
Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma (2022) (0)
An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma. (2021) (0)
New antibodies in the treatment of lymphoma. (2006) (0)
Abstract IA08: Reprogramming human cancer cells in CDK4/6 inhibitor therapy (2016) (0)
Abstract 4895: Hodgkin lymphoma patients demonstrate evidence of chronic activation/exhaustion in circulating T cell subsets (2016) (0)
Phase I /II T rial o f E pratuzumab ( Humanized A nti-CD22 Antibody) i n I ndolent N on-Hodgkin's L ymphoma (2003) (0)
Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes, (2011) (0)
USE OF IL-12 AND IL-12 antagonist for the manufacture of a medicament FOR TREATMENT OF AUTOIMMUNE DISEASE (1995) (0)
Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL (2013) (0)
Factors Impacting Treatment Decision Making in Older Adults With Indolent Non-Hodgkin Lymphoma (2021) (0)
Secretion and not Restricted to T and NK γ IFN-Expression Is Independent of Secondary Autocrine Regulation of IL-12 Receptor and (1999) (0)
25 Monoclonal Antibodies in Lymphomas (0)
Abstract IA28: PI3K and mTOR inhibitors in lymphoid malignancies: Clinical data (2015) (0)
Novel functional assessment techniques for geriatric lymphoma patients. (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John Paul Leonard?

John Paul Leonard is affiliated with the following schools:

Cornell University
University of Pittsburgh
University of Texas Southwestern Medical Center